Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A

Healthy Volunteer Clinical Trial

Official title:

A Phase 1, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effect of the Modulators of the Cytochrome P450 (CYP) 2C8 and/or 3A on the Single-Dose Pharmacokinetics of Ozanimod and CC112273 in Healthy Adult Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03624959
• Other study ID #: RPC01-1912
• Secondary ID: U1111-1215-6965
• Status: Completed
• Phase: Phase 1
• Start date: June 20, 2018
• Est. completion date: August 10, 2018

Study information

• Verified date: May 2019
• Source: Celgene
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effect of the following index inhibitors or inducers of CYP2C8 and/or CYP3A on the single-dose pharmacokinetics (PK) of ozanimod and its major active metabolite, CC112273, in healthy adult subjects: gemfibrozil (strong inhibitor of CYP2C8), rifampin (moderate inducer of CYP2C8 and strong inducer of CYP3A), and itraconazole (strong inhibitor of CYP3A).

Study Design

This is a Phase 1, randomized, parallel-group, open-label study with two parts, 1 and 2. Forty subjects will be enrolled in Part 1 and will be randomized into 1 of the 2 treatment groups, with 20 subjects in each treatment group. Sixty subjects will be enrolled in Part 2 and will be randomized into 1 of the 3 treatment groups, with 20 subjects in each treatment group. . Study parts and treatment groups are as follow:

Part 1:

• Treatment Group A (reference): A single dose of ozanimod.

• Treatment Group B (test): Gemfibrozil 600 mg twice daily (BID) on Days 1 through 17. On Day 4, a single dose of ozanimod will be coadministered with the morning dose of gemfibrozil.

Part 2:

• Treatment Group C (reference): A single dose of ozanimod.

• Treatment Group D (test): Itraconazole 200 mg once daily (QD) on Days 1 through 17. On Day 4, a single dose of ozanimod will be coadministered with itraconazole.

• Treatment Group E (test): Rifampin 600 mg QD on Days 1 through 21. On Day 8, a single dose of ozanimod will be coadministered with rifampin.

Study Population Subjects will be healthy men and non-pregnant, non-lactating women, ages 18 to 55 years, inclusive, with a body weight of at least 110 pounds (50 kg); body mass index (BMI) within the range of 18.0 to 30.0 kg/m2, inclusive.

Length of Study The study duration ranges from 43 days to 50 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: August 10, 2018
• Est. primary completion date: August 10, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Subject is a man or non-pregnant, non-lactating woman, ages 18 to 55 years, inclusive, at the time of signing of the informed consent form (ICF).

2. Female subjects must meet at least 1 of the following criteria:

• Negative serum pregnancy test at Screening and Day -1 (women of child-bearing potential [WOCBP] only).

• Postmenopausal (defined as 2 years after the last period and follicle-stimulating hormone [FSH] > 40 IU/L).

• Received surgical sterilization (eg, bilateral tubal ligation, bilateral oophorectomy, hysterectomy) at least 6 months before Screening with medical records.

3. Females of child-bearing potential:

Must agree to practice a highly effective method of contraception throughout the study until completion of the 75-day Safety Follow-up. Highly effective methods of contraception are those that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly.

Acceptable methods of birth control in this study are the following:

• Combined hormonal (oestrogen and progestogen containing) contraception, which may be oral, intravaginal, or transdermal

• Progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, implantable

• Placement of an intrauterine device or intrauterine hormone-releasing system

• Bilateral tubal occlusion

• Vasectomized partner

• Sexual abstinence

Male subjects:

Must agree to use a latex condom with spermicide during sexual contact with WOCBP while participating in the study and until completion of the 75-day Safety Follow-up.

All subjects:

Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together.

4. Male subjects must agree to refrain from donating sperm throughout the study and until completion of the 75-day Safety Follow-up.

5. Subject has a body weight of at least 110 pounds (50 kg); body mass index (BMI) within the range of 18.0 to 30.0 kg/m2, inclusive (Screening and Day -1).

6. Subject is in good health, as determined by no clinically significant findings from medical or surgical history, 12-lead ECG, physical examination, clinical laboratory tests, and vital signs.

7. Subject must be able to comprehend and provide written informed consent, and must be able to comply with the requirements of the study, including the study visit schedule and other protocol requirements.

Exclusion Criteria:

1. Subject with a seated blood pressure outside 90 to 140 mmHg systolic or 50 to 90 mmHg diastolic at Screening or Day -1.

2. Subject with a seated pulse rate outside 55 to 90 bpm at Screening or Day -1.

3. Subject has a presence or history of any abnormality or illness that, in the opinion of the investigator, may affect absorption, distribution, metabolism, or elimination of the Investigational product (IP) or would limit the subject's ability to participate in and complete this clinical study.

4. Subject has a history of alcoholism, drug abuse, or addiction within 24 months prior to Screening.

5. Subject has a positive serum test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).

6. Subject has used any tobacco- or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, electronic cigarettes, vape, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) or marijuana (cigarette, joint, vape, edibles, etc) within 3 months prior to the first dose of IP.

7. Subject has a positive urine drug test including cotinine at Screening or Day -1.

8. Subject has a positive alcohol urine or breath test at Screening or Day -1.

9. Subject has received any investigational drug within 30 days or 5 times the elimination half-life (if known), whichever is longer, prior to the first dose of IP.

10. Subject has used any systemic over-the-counter medication (excluding acetaminophen up to 1 g/day), dietary or herbal supplement (excluding vitamins/multivitamins) within 7 days prior to the first dose of IP. St. John's wort, naringenin, curcurmin/turmeric, passion flower, and quercetin must be discontinued at least 28 days prior to the first dose of IP.

11. Subject has used any systemic prescription medication (excluding hormonal contraceptives) within 28 days or 5 times the elimination half-life, whichever is longer, prior to the first dose of IP.

12. Subject has ingested alcohol within 7 days prior to the first dose of IP.

13. Subject fails or is unwilling to abstain from strenuous physical activities for at least 24 hours prior to the first dose of IP.

14. Subject has poor peripheral venous access.

15. Subject has donated greater than 400 mL of blood within 60 days prior to Day 1.

16. Subject has a history of any medical condition or medical history that, in the opinion of the investigator, might confound the results of the study or jeopardize the safety or welfare of the subject.

17. Subject has history of hypersensitivity or allergic reaction to S1P receptor modulators (both Parts 1 and 2), gemfibrozil (Part 1 only), itraconazole or other azole antifungals (Part 2 only), or rifampin (Part 2 only).

18. Subject has a history of gall bladder disease (Part 2 only).

Related Conditions & MeSH terms

• Healthy Volunteer

Intervention

Drug:
• Ozanimod
ozanimod
• Gemfibrozil
Gemfibrozil
• Itraconazole
Itraconazole
• Rifampin
Rifampin

Locations

Country	Name	City	State
United States	PPD Phase 1 Clinic	Austin	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Celgene

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics- Cmax	Maximum observed plasma concentration	Up to 14 days after ozanimod dosing
Primary	Pharmacokinetics- AUC8	Area under the concentration-time curve from time 0 to infinity	Up to 14 days after ozanimod dosing
Primary	Pharmacokinetics- AUC0-14d	Area under the concentration-time curve from time 0 to 14 days post dose	Up to 14 days after ozanimod dosing
Secondary	Adverse Events (AEs)	The incidence, severity, and relationship of TEAEs	From enrollment until at least 75 days after ozanimod dosing
Secondary	Pharmacokinetics- Tmax	Time to Cmax	Up to 14 days after ozanimod dosing
Secondary	Pharmacokinetics- CL/F	Apparent oral clearance	Up to 14 days after ozanimod dosing
Secondary	Pharmacokinetics- Vz/F	Apparent volume of distribution during terminal phase after oral administration	Up to 14 days after ozanimod dosing
Secondary	Pharmacokinetics- ?z	Terminal elimination rate constant	Up to 14 days after ozanimod dosing
Secondary	Pharmacokinetics- t1/2	Terminal elimination half-life	Up to 14 days after ozanimod dosing